Empagliflozin and Hepatic Glucose Metabolism

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT03193684
Phase
PHASE4
Status
Completed

Conditions

  • Hepatic Glucose Metabolism

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Empagliflozin 25 MG — DRUG
    subjects will receive daily dose of 25mg of empagliflozin for 3 months
  • Control — DRUG
    Placebo

Study Details

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

Key Dates

Start date
May 20, 2018
Status verified
Aug 2024
Primary completion
Jan 30, 2023
Completion
Jan 30, 2024

Study Design

Enrollment
72 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Treatment
    empagliflozin 25 mg per day
  • Placebo Comparator: control
    matching placebo 1 pill per day

Primary Outcome Measure

Effect of Empagliflozin on Autonomic Nervous System [ Time Frame: Baseline and 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes Division, UTHSCSASan AntonioTexas78229-

Find similar trials in San Antonio, TX

By research site
Diabetes Division, UTHSCSA· San Antonio, TX